Nivolumab + Ipilimumab clinical trials

Immunotherapy With Ipilimumab and Nivolumab Preceded or Not by a Targeted Therapy With Encorafenib and Binimetinib

This study looks at treating advanced melanoma with immunotherapy (nivolumab and ipilimumab) alone, or by starting with targeted therapy (encorafenib and binimetinib) for 12 weeks first. It aims to see if adding the targeted therapy first improves how long people live without their cancer growing.